Accuray Showcases CyberKnife Robotic Radiosurgery System at American Urological Association Meeting
SUNNYVALE, Calif. and WASHINGTON, May 16, 2011 /PRNewswire/ -- The American Urological Association (AUA) Meeting, May 16, 2011 -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that it will showcase the CyberKnife® Robotic Radiosurgery System, used to treat more than 6,500 prostate cancer patients around the world to date, in the company's booth (#3243) at the American Urological Association (AUA) meeting. Accuray will also sponsor a theater presentation on use of the CyberKnife System for prostate cancer, highlighting published long-term data on outcomes and the important role of multidisciplinary teams in treating prostate cancer patients with SBRT. The AUA meeting takes place May 14-17, 2011 in Washington, D.C.
"Recently published five-year data on CyberKnife SBRT for prostate cancer validates the long-term efficacy of prostate SBRT," said Omar Dawood, vice president, medical affairs, Accuray. "This adds to the growing body of clinical evidence in support of the CyberKnife System for prostate cancer. The unique capabilities of our robotic technology to track and correct for prostate movement has helped Accuray solidify our position as a leader in the field of prostate SBRT. In the first quarter of calendar year 2011, we achieved a 20 percent increase in worldwide prostate cancer treatments as compared to the same period last year and look forward to continued wide adoption of this non surgical treatment option."
On Tuesday, May 17 at 3:00 p.m. E.T., Accuray will host a presentation at the AUA Industry Clinical Update Theatre on "CyberKnife Prostate SBRT Outcomes and Experiences." Lee Ponsky, MD, FACS, director of the Center for Urologic Oncology and Minimally Invasive Therapies at University Hospitals Case Medical Center in Cleveland, and Debra Freeman, MD, senior manager of clinical development at Accuray and oncologist affiliated with Naples Radiation Oncology, will provide an overview of the CyberKnife System and recently published five-year outcomes data on stereotactic body radiotherapy (SBRT) using the CyberKnife System for the treatment of localized, low-risk prostate cancer. The presentation will be followed by a discussion on the role of surgeons as part of a multi-disciplinary team in treating prostate cancer patients with SBRT.
Results of the recently published five-year outcomes on low-risk prostate cancer patients treated with CyberKnife SBRT appeared in the January 10, 2011 issue of Radiation Oncology. The multi-center study, which combined data from 41 patients treated at Stanford University in Stanford, Calif. and Naples Community Hospital in Naples, Fla., showed that 93 percent of patients treated with the CyberKnife System had no recurrence of their cancer at a median follow-up of five years. This rate compares favorably to results obtained with other treatment modalities, including surgery and conventional radiation therapy. In addition, the study demonstrates excellent long term urinary and rectal toxicity results for this short, outpatient five day course of CyberKnife SBRT.
CyberKnife SBRT is a non-invasive treatment option for prostate cancer that can achieve high rates of disease control while sparing critical nearby structures, thereby minimizing undesirable side effects typically associated with other treatment modalities and preserving patients' quality of life. Unlike gantry based systems, the CyberKnife System is the only technology on the market capable of both tracking and automatically correcting for the unpredictable movement of the prostate during treatment. Utilizing its unique robotic platform, the CyberKnife System enables clinicians to deliver highly precise doses of radiation in three dimensions with small treatment margins that minimize radiation doses to critical structures including the rectum, urethra and neurovascular bundles. Additionally, CyberKnife SBRT provides patients a pain-free treatment option that's completed in five or fewer treatment sessions, resulting in minimal interruption to their daily lives.
Attendees interested in participating in the theater presentation may register online.
Media interested in meeting with Accuray at AUA can contact Jenny Ng or Marisa Borgasano at Accuray@schwartzcomm.com or 781-684-0770.
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 100,000 patients worldwide and currently more than 226 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical experience and market acceptance are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: range of treatment options, clinical applications, and market acceptance of products and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2010 fiscal year, our form 10-Q filed on May 10, 2011 and our other filings with the Securities and Exchange Commission.. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Omar Dawood, M.D., MPH
Euan Thomson, Ph.D.
SOURCE Accuray Incorporated